EntryPoint Capital LLC Invests $223,000 in Ionis Pharmaceuticals, Inc. (NASDAQ:IONS)

EntryPoint Capital LLC bought a new stake in Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) in the fourth quarter, according to its most recent filing with the Securities & Exchange Commission. The firm bought 6,382 shares of the company’s stock, valued at approximately $223,000.

Several other institutional investors and hedge funds have also recently bought and sold shares of IONS. Signaturefd LLC boosted its stake in shares of Ionis Pharmaceuticals by 160.0% in the 4th quarter. Signaturefd LLC now owns 949 shares of the company’s stock valued at $33,000 after buying an additional 584 shares during the period. Lindbrook Capital LLC lifted its stake in Ionis Pharmaceuticals by 183.8% in the fourth quarter. Lindbrook Capital LLC now owns 1,036 shares of the company’s stock worth $36,000 after acquiring an additional 671 shares during the last quarter. Itau Unibanco Holding S.A. grew its holdings in Ionis Pharmaceuticals by 40.9% during the 3rd quarter. Itau Unibanco Holding S.A. now owns 1,081 shares of the company’s stock worth $43,000 after acquiring an additional 314 shares in the last quarter. Quantbot Technologies LP purchased a new stake in shares of Ionis Pharmaceuticals in the 3rd quarter valued at approximately $51,000. Finally, Quest Partners LLC raised its holdings in shares of Ionis Pharmaceuticals by 94.8% in the 3rd quarter. Quest Partners LLC now owns 2,674 shares of the company’s stock valued at $107,000 after purchasing an additional 1,301 shares in the last quarter. 93.86% of the stock is owned by institutional investors and hedge funds.

Insider Buying and Selling

In other news, CEO Brett P. Monia sold 33,445 shares of the firm’s stock in a transaction on Thursday, January 16th. The stock was sold at an average price of $32.63, for a total value of $1,091,310.35. Following the completion of the transaction, the chief executive officer now owns 207,396 shares in the company, valued at $6,767,331.48. This trade represents a 13.89 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Also, CFO Elizabeth L. Hougen sold 8,870 shares of the business’s stock in a transaction dated Thursday, January 16th. The stock was sold at an average price of $32.81, for a total transaction of $291,024.70. Following the completion of the sale, the chief financial officer now owns 107,885 shares in the company, valued at $3,539,706.85. This represents a 7.60 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 111,956 shares of company stock valued at $3,608,439. 2.71% of the stock is owned by insiders.

Ionis Pharmaceuticals Trading Down 1.8 %

Shares of IONS stock opened at $31.15 on Friday. The firm has a market capitalization of $4.95 billion, a PE ratio of -10.25 and a beta of 0.28. Ionis Pharmaceuticals, Inc. has a 1-year low of $30.23 and a 1-year high of $52.34. The business’s fifty day moving average price is $32.53 and its 200 day moving average price is $35.75. The company has a debt-to-equity ratio of 2.12, a current ratio of 8.47 and a quick ratio of 8.82.

Ionis Pharmaceuticals (NASDAQ:IONS) last posted its quarterly earnings results on Wednesday, February 19th. The company reported ($0.66) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($1.12) by $0.46. The company had revenue of $227.00 million during the quarter, compared to the consensus estimate of $140.97 million. Ionis Pharmaceuticals had a negative net margin of 64.25% and a negative return on equity of 100.05%. The company’s revenue for the quarter was down 30.2% on a year-over-year basis. During the same period last year, the firm earned $0.12 EPS. As a group, sell-side analysts forecast that Ionis Pharmaceuticals, Inc. will post -3.5 EPS for the current fiscal year.

Analyst Ratings Changes

Several equities analysts recently commented on IONS shares. StockNews.com raised Ionis Pharmaceuticals to a “sell” rating in a report on Tuesday, March 18th. JPMorgan Chase & Co. cut their target price on Ionis Pharmaceuticals from $47.00 to $45.00 and set a “neutral” rating on the stock in a research report on Monday, March 24th. BMO Capital Markets lowered their price target on Ionis Pharmaceuticals from $60.00 to $45.00 and set a “market perform” rating for the company in a report on Thursday, February 20th. Needham & Company LLC reissued a “buy” rating and set a $60.00 price objective on shares of Ionis Pharmaceuticals in a report on Thursday, February 20th. Finally, William Blair restated an “outperform” rating on shares of Ionis Pharmaceuticals in a report on Friday, December 20th. Two research analysts have rated the stock with a sell rating, five have issued a hold rating, thirteen have assigned a buy rating and one has issued a strong buy rating to the company’s stock. According to data from MarketBeat, Ionis Pharmaceuticals has an average rating of “Moderate Buy” and a consensus target price of $59.44.

Ionis Pharmaceuticals Profile

Ionis Pharmaceuticals, Inc discovers and develops RNA-targeted therapeutics in the United States. The company offers SPINRAZA for spinal muscular atrophy (SMA) in pediatric and adult patients; TEGSEDI, an antisense injection for the treatment of polyneuropathy caused by hereditary transthyretin amyloidosis in adults; and WAYLIVRA, an antisense medicine for treatment for familial chylomicronemia syndrome (FCS) and familial partial lipodystrophy.